← Leaderboards
Michael Hindle
Virginia Commonwealth University
$5,431,031
Attributed
$10,533,902
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2010–21$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$9,950,878 · 4
FDA$583,024 · 1
By mechanism
R01$9,542,723 · 3
U01$583,024 · 1
R21$408,155 · 1
Top collaborators
- P. Worth Longest19 shared
- Peter R Byron1 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- P. Worth Longest$9,813,926
- Jarrod Mosier$733,737
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseGrowthParticleLungAerosolsIn VitroDevicesExcipientsDepositionNebulizerAdultLiquid SubstanceNoseParticle SizeCystic FibrosisPharmaceutical PreparationsSimulationBaseRespiratoryWettabilityCannulasDrug Delivery SystemsFormulationInhalation Therapy
Grant awards (22)
High Efficiency Delivery of Surfactant Aerosols to Infants without Intubation$734,852
R01 · FY2021 · HL
High Efficiency Inhalation Delivery of Tobramycin for Children with Cystic Fibrosis$475,680
R01 · FY2021 · HD
High Efficiency Delivery of Surfactant Aerosols to Infants without Intubation$723,687
R01 · FY2020 · HL
High Efficiency Aerosol Delivery using the Excipient Enhanced Growth Concept: A Human Proof of Concept Study$612,895
R01 · FY2020 · HL
High Efficiency Inhalation Delivery of Tobramycin for Children with Cystic Fibrosis$517,950
R01 · FY2020 · HD
High Efficiency Delivery of Surfactant Aerosols to Infants without Intubation$688,568
R01 · FY2019 · HL
High Efficiency Aerosol Delivery using the Excipient Enhanced Growth Concept: A Human Proof of Concept Study$597,412
R01 · FY2019 · HL
High Efficiency Inhalation Delivery of Tobramycin for Children with Cystic Fibrosis$527,772
R01 · FY2019 · HD
High Efficiency Delivery of Surfactant Aerosols to Infants without Intubation$692,453
R01 · FY2018 · HL
High Efficiency Aerosol Delivery using the Excipient Enhanced Growth Concept: A Human Proof of Concept Study$577,528
R01 · FY2018 · HL
High Efficiency Inhalation Delivery of Tobramycin for Children with Cystic Fibrosis$519,041
R01 · FY2018 · HD
High Efficiency Aerosol Delivery using the Excipient Enhanced Growth Concept: A Human Proof of Concept Study$585,153
R01 · FY2017 · HL
High Efficiency Inhalation Delivery of Tobramycin for Children with Cystic Fibrosis$489,791
R01 · FY2017 · HD
Development of Clinically Relevant in Vitro Performance Test for Generic OIDPs$93,727
U01 · FY2016 · FD · contact PI
Effective Delivery of Pharmaceutical Aerosols during Non-Invasive Ventilation$428,345
R01 · FY2015 · HL
Development of Clinically Relevant in Vitro Performance Test for Generic OIDPs$234,433
U01 · FY2015 · FD · contact PI
Effective Delivery of Pharmaceutical Aerosols during Non-Invasive Ventilation$432,679
R01 · FY2014 · HL
Development of Clinically Relevant in Vitro Performance Test for Generic OIDPs$254,864
U01 · FY2014 · FD · contact PI
Effective Delivery of Pharmaceutical Aerosols during Non-Invasive Ventilation$466,534
R01 · FY2012 · HL
Effective Delivery of Pharmaceutical Aerosols during Non-Invasive Ventilation$472,383
R01 · FY2011 · HL
Excipient enhanced aerosol particle formulations and inhaler development for impr$224,250
R21 · FY2011 · HL · contact PI
Excipient enhanced aerosol particle formulations and inhaler development for impr$183,905
R21 · FY2010 · HL · contact PI